Home / Resources / On-Demand Webinar / Phoenix WinNonlin Workflows: Estimate Pre-clinical PK/PD Parameters for Anti-cancer Agents
Phoenix WinNonlin Workflows: Estimate Pre-clinical PK/PD Parameters for Anti-cancer Agents

On-Demand Webinar

Are you utilizing Phoenix WinNonlin to effectively evaluate the safety, efficacy and target specificity of investigational drugs? Are you building workflows from scratch for every new drug compound? Learn how to use Phoenix templates to accelerate characterizing a drug’s PK/PD profile. In this webinar, Certara’s Dr. Bernd Wendt demonstrated how Phoenix WinNonlin has been used to rank anti-cancer compounds according to their efficacy to ultimately select which to promote to clinical development.

About Our Speaker

Dr. Bernd Wendt, Director of Training & Support, Certara. Dr. Bernd Wendt has more than 15 years experience in the life science industry, specializing in molecular design and data mining techniques. Before joining Certara he was heading the Molecular and PK modeling lab for Elara Pharmaceuticals, a spinoff from the European Molecular Biology Labs (EMBL), focussing on the development of new therapies in the field of oncology. Prior to this, Dr. Wendt worked for Tripos’ Chemistry Research Centre in the UK where he was a project and strategic alliance manager. Dr. Wendt gained his Diploma and Ph.D. In Chemistry/Biochemistry at the Philipps University Marburg, Germany.

Are you utilizing Phoenix WinNonlin to effectively evaluate the safety, efficacy and target specificity of investigational drugs? Are you building workflows from scratch for every new drug compound? Learn how to use Phoenix templates to accelerate characterizing a drug’s PK/PD profile. In this webinar, Certara’s Dr. Bernd Wendt demonstrated how Phoenix WinNonlin has been used to rank anti-cancer compounds according to their efficacy to ultimately select which to promote to clinical development.

Back to top